DMRA
Damora Therapeutics, Inc. (DMRA) reported net income of -$209.84M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$209.84M | -878.8% |
| FY 2024 | -$21.44M | +44.1% |
| FY 2023 | -$38.35M | +37.8% |
| FY 2022 | -$61.62M | -19.1% |
| FY 2021 | -$51.75M | -48.6% |
| FY 2020 | -$34.84M | +4.6% |
| FY 2019 | -$36.51M | - |
Damora Therapeutics, Inc. (DMRA) reported net income of -$209.84M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Damora Therapeutics, Inc.'s net income declined from -$36.51M to -$209.84M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.